Structure Therapeutics Inc. Capital Expenditures
Structure Therapeutics Inc. (GPCR) reported Capital Expenditures of $1.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was -$42.00K, a 118.10% decline year-over-year.
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $1.18M, a 276.43% increase year-over-year.
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $1.50M, a 9250.00% increase year-over-year.
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $1.57M, a 129.49% increase year-over-year.
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $3.61M, a 180.16% increase from fiscal 2024.
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $1.29M, a 40.47% decline from fiscal 2023.
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $2.17M, a 1298.06% increase from fiscal 2022.
- Structure Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $155.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.14M 10-Q · filed 2026-08-06 | $2.64M derived: sum of 3 quarters · filed 2026-08-06 | $4.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.18M 10-Q · filed 2026-05-07 | $2.68M derived: sum of 2 quarters · filed 2026-05-07 | $4.25M derived: sum of 3 quarters · filed 2026-05-07 | $4.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.07M derived: sum of 2 quarters · filed 2026-02-26 | $3.30M derived: sum of 3 quarters · filed 2026-08-06 | $3.61M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.80M derived: sum of 2 quarters · filed 2026-08-06 | $2.12M 10-Q · filed 2025-11-06 | $2.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $546.00K 10-Q · filed 2026-08-06 | $562.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $314.00K 10-Q · filed 2026-05-07 | $330.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.01M derived: sum of 3 quarters · filed 2026-05-07 | $1.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $701.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.13M derived: sum of 3 quarters · filed 2026-02-26 | $1.29M 10-K · filed 2026-02-26 |
| 2024-09-30 | $685.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.11M derived: sum of 2 quarters · filed 2025-11-06 | $1.27M 10-Q · filed 2025-11-06 | $2.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $427.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $589.00K 10-Q · filed 2025-08-06 | $1.75M derived: sum of 3 quarters · filed 2026-02-26 | $2.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $162.00K 10-Q · filed 2025-05-08 | $1.32M derived: sum of 2 quarters · filed 2026-02-26 | $2.14M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.98M derived: sum of 2 quarters · filed 2026-02-26 | $2.17M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $820.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.01M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $191.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $143.00K derived: sum of 2 quarters · filed 2024-03-08 | $90.00K derived: sum of 3 quarters · filed 2024-03-08 | $155.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $72.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | $19.00K derived: sum of 2 quarters · filed 2023-11-17 | $84.00K 10-Q · filed 2023-11-17 | |
| 2022-06-30 | -$53.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $12.00K 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $65.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |